Business Description

Calithera Biosciences Inc
NAICS : 325412
SIC : 2834
ISIN : US13089P1012
Compare
Compare
Traded in other countries / regions
CALA.USA2CB0.Germany IPO Date
2014-10-02Description
Calithera Biosciences Inc is a clinical-stage pharmaceutical company. The business activity of the firm functions through the region of the United States. It focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. Its product candidate is CB-839, an inhibitor of glutaminase for the treatment of solid tumors. Its other product candidate, CB-1158, is being developed for hematology and oncology indications.
Financial Strength
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 15.28 | |||||
Equity-to-Asset | 0.71 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 40.1 | |||||
3-Year EPS without NRI Growth Rate | 40.7 | |||||
3-Year FCF Growth Rate | 35.9 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 55.51 | |||||
9-Day RSI | 49.27 | |||||
14-Day RSI | 39.52 | |||||
6-1 Month Momentum % | -9.09 | |||||
12-1 Month Momentum % | -98.31 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 3.6 | |||||
Quick Ratio | 3.6 | |||||
Cash Ratio | 3.44 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -15.3 | |||||
Shareholder Yield % | 7.96 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -227.15 | |||||
ROA % | -87.6 | |||||
ROIC % | -950.09 | |||||
ROC (Joel Greenblatt) % | -1739.6 | |||||
ROCE % | -119.93 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | 0.03 | |||||
EV-to-EBITDA | 0.03 | |||||
EV-to-FCF | 0.03 | |||||
Price-to-Net-Cash | 0.01 | |||||
Earnings Yield (Greenblatt) % | 3333.33 |
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CALA
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Calithera Biosciences Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -8.65 | ||
Beta | -0.79 | ||
Volatility % | 1737.62 | ||
14-Day RSI | 39.52 | ||
14-Day ATR ($) | 0.0077 | ||
20-Day SMA ($) | 0.0499 | ||
12-1 Month Momentum % | -98.31 | ||
52-Week Range ($) | 0.01 - 3.6838 | ||
Shares Outstanding (Mil) | 4.87 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Calithera Biosciences Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Calithera Biosciences Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Calithera Biosciences Inc Frequently Asked Questions
What is Calithera Biosciences Inc(CALA)'s stock price today?
The current price of CALA is $0.05. The 52 week high of CALA is $3.68 and 52 week low is $0.01.
When is next earnings date of Calithera Biosciences Inc(CALA)?
The next earnings date of Calithera Biosciences Inc(CALA) is 2023-11-09 Est..
Does Calithera Biosciences Inc(CALA) pay dividends? If so, how much?
Calithera Biosciences Inc(CALA) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |